Novo Nordisk (NVO) might just be the comeback story of the year. Despite being down 52% over the past 12 months, the pharma giant is still dominating diabetes and obesity treatments — and the current dip could be a golden buying opportunity.
The company’s cutting-edge drug pipeline, including CagriSema and Amycretin, is packed with potential. Even though recent trial results didn’t blow Wall Street away, Novo Nordisk’s fundamentals remain rock-solid. Revenue is growing, profits are strong, and it’s expanding into new markets like rare and neurological diseases.
With a forward P/E below the market average and continued innovation in its core markets, Novo could realistically double investor money within six years — especially if you’re reinvesting dividends.
This post appeared on Trades Of The Day